BioCentury
ARTICLE | Finance

Early bird Avalon

Afraxis sale to Genentech gives Avalon Ventures second early stage exit in 2013

February 4, 2013 8:00 AM UTC

Avalon Ventures has hit the ground running in 2013 with two exits thus far and a third waiting in the wings.

Just three weeks after BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) bought Zacharon Pharmaceuticals Inc., Genentech Inc. last week acquired the entire therapeutic business of a second Avalon portfolio company, Afraxis Inc...